Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
Interventions: DRUG: dalpiciclib; fluvestrant; compound gossypol acetate tablets
Sponsor: Zhejiang Cancer Hospital